Pharmaceuticals

After 40 years, capsule giant CapsCanada becomes Lyfe Group, a strategic move to unify its brand, leverage new investments, and lead the drug delivery market.

Sesen launches a new platform blending AI and human experts to streamline complex medical translation, aiming for faster, safer global market access.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A massive $250M investment could replace a 40-pill daily burden with a single tablet for patients with pancreatic insufficiency, disrupting a market in crisis.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

ABEC's expanded group integrates advanced modeling and custom engineering to accelerate drug development, reduce risk, and boost manufacturing efficiency.

With a key FDA decision looming, Cristcot hires Rayna Herman to lead the commercial strategy for its first-in-class ulcerative colitis therapy, ngHCA.

The architect of HUMIRA's launch and Horizon's $28B sale is now shaping the next wave of drug companies from within private equity. What does it mean?

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Amble Health's new program offers 50% off weight loss drugs, but it requires patients to pay cash and potentially use non-FDA-approved medications.

Alcami acquires Tjoapack, creating a transatlantic CDMO. The deal, orchestrated by owner Ampersand Capital, signals a major shift in pharma services.

With six new collaborations, the life science leader aims to tame data complexity and accelerate discovery by creating a single, integrated software ecosystem.

With a novel 'NewCo' model and key partnerships, Banyan BioInnovations aims to de-risk and accelerate clinical-stage drugs past the funding valley of death.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

A biotech firm is making waves with a non-viral, redosable gene delivery system showing promise for DMD and hemophilia, challenging the industry's reliance on viruses.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.